Adenoma
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Adenoma is a moderately active landscape with 40 programs across 18 companies. The most active players are Merck & Co., Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Tiburio Therapeutics. 6 therapies are approved with 7 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Merck & Co.
1 program
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
2 programs
Tiburio Therapeutics
1 program
Eli Lilly
1 program
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
1 program
Eisai
1 program
Pipeline
Programs by Phase
Analysis
Modality Breakdown
87%
Small molecule
39 of 45 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 45 classified programs, each share of the total. Modality classified for 100% of 46 pipeline programs.
Analysis
Trial Status
51
clinical trials
Clinical Trials
Trial Activity
51 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)